TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:13
DEXCOM INC ( DXCM ) https://www.dexcom.com
139.93USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
DXCM
22.95%
SPY
32.74%
-60.33%
DXCM
SPY
92.93%
DXCM
17.49%
SPY
224.41%
DXCM
249.48%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
51416.21
48920.81
3.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
136.38
15.11
24.86
1.63
0.00
74.70
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
21.08
63.93
18.38
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.8206
14.59
19.90
1.22
Other Earnings and Cash Flow Stats:
DEXCOM INC ( DXCM ) Net Income TTM ($MM) is 362.30
DEXCOM INC ( DXCM ) Operating Income TTM ($MM) is 547.50
DEXCOM INC ( DXCM ) Owners' Earnings Annual ($MM) is 380.68
DEXCOM INC ( DXCM ) Current Price to Owners' Earnings ratio is 141.67
DEXCOM INC ( DXCM ) EBITDA TTM ($MM) is 647.60
DEXCOM INC ( DXCM ) EBITDA Margin is 18.38%
Capital Allocation:
DEXCOM INC ( DXCM ) has paid 0.00 dividends per share and bought back 42.1 million shares in the past 12 months
DEXCOM INC ( DXCM ) has reduced its debt by 2836.9 million USD in the last 12 months
Capital Structure:
DEXCOM INC ( DXCM ) Interest-bearing Debt ($MM) as of last quarter is 101
DEXCOM INC ( DXCM ) Annual Working Capital Investments ($MM) are 201
DEXCOM INC ( DXCM ) Book Value ($MM) as of last quarter is 2068
DEXCOM INC ( DXCM ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
DEXCOM INC ( DXCM ) has 566 million in cash on hand as of last quarter
DEXCOM INC ( DXCM ) has 1556 million of liabilities due within 12 months, and long term debt 2556 as of last quarter
DEXCOM INC ( DXCM ) has 385 common shares outstanding as of last quarter
DEXCOM INC ( DXCM ) has 0 million USD of preferred stock value
Academic Scores:
DEXCOM INC ( DXCM ) Altman Z-Score is 9.02 as of last quarter
DEXCOM INC ( DXCM ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
DEXCOM INC ( DXCM ) largest shareholder is Blair William & Co owning 4468004 shares at 625.21 ($MM) value
Dolan Matthew Vincent(an insider) Sold 1003 shares of DEXCOM INC ( DXCM ) for the amount of $131785.37 on 2024-03-15
0.39% of DEXCOM INC ( DXCM ) is held by insiders, and 100.65% is held by institutions
DEXCOM INC ( DXCM ) went public on 2005-04-14
Other DEXCOM INC ( DXCM ) financial metrics:
FCF:553.50
Unlevered Free Cash Flow:210.00
EPS:1.25
Operating Margin:21.08
Gross Profit Margin:63.93
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:23.34
Beta:1.22
Buffet's Owners Earnings:380.68
Price to Owner's Earnings:141.67
About DEXCOM INC ( DXCM ) :
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.